These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 23411384)

  • 21. Multigene prognostic tests in breast cancer: past, present, future.
    Győrffy B; Hatzis C; Sanft T; Hofstatter E; Aktas B; Pusztai L
    Breast Cancer Res; 2015 Jan; 17(1):11. PubMed ID: 25848861
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of Oncotype DX on treatment decisions in ER-positive, node-negative breast cancer with histologic correlation.
    Biroschak JR; Schwartz GF; Palazzo JP; Toll AD; Brill KL; Jaslow RJ; Lee SY
    Breast J; 2013; 19(3):269-75. PubMed ID: 23614365
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Real-world use of multigene signatures in early breast cancer: differences to clinical trials.
    Licata L; De Sanctis R; Vingiani A; Cosentini D; Iorfida M; Caremoli ER; Sassi I; Fernandes B; Gianatti A; Guerini-Rocco E; Zambelli C; Munzone E; Simoncini EL; Tondini C; Gentilini OD; Zambelli A; Pruneri G; Bianchini G
    Breast Cancer Res Treat; 2024 May; 205(1):39-48. PubMed ID: 38265569
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Multigene assays in early breast cancer: Insights from recent phase 3 studies.
    Markopoulos C; Hyams DM; Gomez HL; Harries M; Nakamura S; Traina T; Katz A
    Eur J Surg Oncol; 2020 Apr; 46(4 Pt A):656-666. PubMed ID: 31706719
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Factors influencing Oncotype DX use in the management of early breast cancer: a single centre experience.
    Zhu X; Dent S; Paquet L; Zhang T; Graham N; Song X
    Eur J Cancer; 2014 Oct; 50(15):2544-9. PubMed ID: 25129366
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chemotherapy benefit for 'ER-positive' breast cancer and contamination of nonluminal subtypes—waiting for TAILORx and RxPONDER.
    Sun Z; Prat A; Cheang MCU; Gelber RD; Perou CM
    Ann Oncol; 2015 Jan; 26(1):70-74. PubMed ID: 25355719
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Impact of the Oncotype DX Breast Cancer Assay on Treatment Decisions for Women With Estrogen Receptor-Positive, Node-Negative Breast Carcinoma in Hong Kong.
    Leung RC; Yau TC; Chan MC; Chan SW; Chan TW; Tsang YY; Wong TT; Chao C; Yoshizawa C; Soong IS; Kwan WH; Kwok CC; Suen JS; Ngan RK; Cheung PS
    Clin Breast Cancer; 2016 Oct; 16(5):372-378. PubMed ID: 27105769
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Results of PONDx, a prospective multicenter study of the Oncotype DX
    Curtit E; Vannetzel JM; Darmon JC; Roche S; Bourgeois H; Dewas S; Catala S; Mereb E; Fanget CF; Genet D; Forest AM; Bernier C; Pivot X
    Breast; 2019 Apr; 44():39-45. PubMed ID: 30634106
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The impact of a genomic assay (Oncotype DX) on adjuvant treatment recommendations in early breast cancer.
    de Boer RH; Baker C; Speakman D; Chao CY; Yoshizawa C; Mann GB
    Med J Aust; 2013 Aug; 199(3):205-8. PubMed ID: 23909545
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: ASCO Clinical Practice Guideline Update-Integration of Results From TAILORx.
    Andre F; Ismaila N; Henry NL; Somerfield MR; Bast RC; Barlow W; Collyar DE; Hammond ME; Kuderer NM; Liu MC; Van Poznak C; Wolff AC; Stearns V
    J Clin Oncol; 2019 Aug; 37(22):1956-1964. PubMed ID: 31150316
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of Oncotype DX breast Recurrence Score testing on adjuvant chemotherapy use in early breast cancer: Real world experience in Greater Manchester, UK.
    Loncaster J; Armstrong A; Howell S; Wilson G; Welch R; Chittalia A; Valentine WJ; Bundred NJ
    Eur J Surg Oncol; 2017 May; 43(5):931-937. PubMed ID: 28111076
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association between partial-volume corrected SUVmax and Oncotype DX recurrence score in early-stage, ER-positive/HER2-negative invasive breast cancer.
    Lee SH; Ha S; An HJ; Lee JS; Han W; Im SA; Ryu HS; Kim WH; Chang JM; Cho N; Moon WK; Cheon GJ
    Eur J Nucl Med Mol Imaging; 2016 Aug; 43(9):1574-84. PubMed ID: 27209424
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of efficacy of 95-gene and 21-gene classifier (Oncotype DX) for prediction of recurrence in ER-positive and node-negative breast cancer patients.
    Naoi Y; Kishi K; Tsunashima R; Shimazu K; Shimomura A; Maruyama N; Shimoda M; Kagara N; Baba Y; Kim SJ; Noguchi S
    Breast Cancer Res Treat; 2013 Jul; 140(2):299-306. PubMed ID: 23884597
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decision Making for Early-Stage, Operable Breast Cancer: American Society of Clinical Oncology Endorsement of Cancer Care Ontario Guideline Recommendations.
    Henry NL; Somerfield MR; Abramson VG; Allison KH; Anders CK; Chingos DT; Hurria A; Openshaw TH; Krop IE
    J Clin Oncol; 2016 Jul; 34(19):2303-11. PubMed ID: 27001586
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of the role of pharmacy technicians in reviewing the eligibility for Oncotype DX genomic test and the impact of the test on treatment plans in breast cancer patients.
    Cheng V; Markarian A; de Lemos ML; Schaff K
    J Oncol Pharm Pract; 2019 Jul; 25(5):1167-1173. PubMed ID: 30348071
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prospective Validation of a Genomic Assay in Breast Cancer: The 70-gene MammaPrint Assay and the MINDACT Trial.
    Audeh W; Blumencranz L; Kling H; Trivedi H; Srkalovic G
    Acta Med Acad; 2019 Apr; 48(1):18-34. PubMed ID: 31264430
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Is oncotype DX recurrence score (RS) of prognostic value once HER2-positive and. low-ER expression patients are removed?
    Milburn M; Rosman M; Mylander C; Tafra L
    Breast J; 2013; 19(4):357-64. PubMed ID: 23701403
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Economic implications of 21-gene breast cancer risk assay from the perspective of an Israeli-managed health-care organization.
    Klang SH; Hammerman A; Liebermann N; Efrat N; Doberne J; Hornberger J
    Value Health; 2010; 13(4):381-7. PubMed ID: 20412544
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Multigene classifiers, prognostic factors, and predictors of breast cancer clinical outcome.
    Ross JS
    Adv Anat Pathol; 2009 Jul; 16(4):204-15. PubMed ID: 19546609
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of Oncotype DX testing on adjuvant treatment decisions in patients with early breast cancer: a single-center study in the United Arab Emirates.
    Jaafar H; Bashir MA; Taher A; Qawasmeh K; Jaloudi M
    Asia Pac J Clin Oncol; 2014 Dec; 10(4):354-60. PubMed ID: 25243360
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.